PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics announced the approval of inducement grants to ten new employees on Nov. 20, 2024. The grants include 18,815 non-statutory stock options and 17,995 restricted stock units (RSUs). The stock options have an exercise price of $41.96 per share and a 10-year term, vesting over four years with 25% vesting on the first anniversary and 6.25% quarterly thereafter. The RSUs vest over four years with 25% vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as part of new hire compensation packages.
PTC Therapeutics ha annunciato l'approvazione di concessioni incentivanti per dieci nuovi dipendenti il 20 novembre 2024. Le concessioni includono 18.815 opzioni su azioni non statutarie e 17.995 unità di azioni vincolate (RSUs). Le opzioni su azioni hanno un prezzo di esercizio di $41,96 per azione e una durata di 10 anni, con un periodo di vesting di quattro anni, in cui il 25% si veste al primo anniversario e il 6,25% trimestralmente successivamente. Le RSUs si vestono nel corso di quattro anni con un 25% che matura annualmente. Queste concessioni sono state approvate secondo la Regola di quotazione Nasdaq 5635(c)(4) come parte dei pacchetti retributivi per i nuovi assunti.
PTC Therapeutics anunció la aprobación de subvenciones incentivadoras para diez nuevos empleados el 20 de noviembre de 2024. Las subvenciones incluyen 18,815 opciones sobre acciones no estatutarias y 17,995 unidades de acciones restringidas (RSUs). Las opciones de acciones tienen un precio de ejercicio de $41.96 por acción y un plazo de 10 años, con un período de adquisición de cuatro años, en el que el 25% se adquiere en el primer aniversario y un 6.25% de manera trimestral a partir de entonces. Las RSUs se adquieren durante cuatro años con un 25% que se madura anualmente. Estas subvenciones fueron aprobadas bajo la Regla de cotización de Nasdaq 5635(c)(4) como parte de los paquetes de compensación para nuevos empleados.
PTC 테라퓨틱스는 2024년 11월 20일에 새로운 직원 10명에게 유인 보조금 승인을 발표했습니다. 보조금에는 18,815개의 비법정 주식 옵션과 17,995개의 제한 주식 단위(RSU)가 포함됩니다. 주식 옵션의 행사가는 $41.96이며, 10년의 기간을 가지며, 4년의 복리 기간 동안 25%는 첫 번째 기념일에, 이후 매 분기마다 6.25%가 발생됩니다. RSU는 4년 동안 25%가 매년 발생됩니다. 이러한 보조금은 새로운 직원 보상 패키지의 일환으로 Nasdaq 상장 규칙 5635(c)(4)에 따라 승인되었습니다.
PTC Therapeutics a annoncé le 20 novembre 2024 l'approbation de subventions incitatives pour dix nouveaux employés. Les subventions comprennent 18 815 options d'achat d'actions non statutaires et 17 995 unités d'actions restreintes (RSUs). Les options d'achat ont un prix d'exercice de $41,96 par action et une durée de 10 ans, avec une période d'acquisition de quatre ans, le vesting de 25 % ayant lieu lors du premier anniversaire et de 6,25 % chaque trimestre par la suite. Les RSUs sont acquises sur une période de quatre ans avec un vesting de 25 % chaque année. Ces subventions ont été approuvées conformément à la règle de cotation Nasdaq 5635(c)(4) dans le cadre des packages de rémunération pour les nouvelles recrues.
PTC Therapeutics gab am 20. November 2024 die Genehmigung von Anreizsubventionen für zehn neue Mitarbeiter bekannt. Die Subventionen umfassen 18.815 nicht-statutären Aktienoptionen und 17.995 beschränkte Aktieneinheiten (RSUs). Die Aktienoptionen haben einen Ausübungspreis von $41,96 pro Aktie und eine Laufzeit von 10 Jahren, wobei ein Vesting über vier Jahre erfolgt, wobei 25 % am ersten Jahrestag und anschließend vierteljährlich 6,25 % fällig werden. Die RSUs werden über einen Zeitraum von vier Jahren mit einer jährlichen Vesting von 25 % fällig. Diese Zuschüsse wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Teil der Vergütungspakete neuer Mitarbeiter genehmigt.
- None.
- None.
The inducement grants were approved by PTC's Compensation Committee on Nov. 20, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn and X.
For more information please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302315812.html
SOURCE PTC Therapeutics, Inc.
FAQ
What is the exercise price of PTC Therapeutics (PTCT) stock options granted on November 20, 2024?
How many stock options and RSUs did PTC Therapeutics (PTCT) grant in November 2024?
What is the vesting schedule for PTC Therapeutics (PTCT) November 2024 stock options?
